

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): June 4, 2019

**Aptose Biosciences Inc.**

(Exact Name of Registrant as Specified in Charter)

**Canada**  
(State or Other Jurisdiction of Incorporation)

**001-32001**  
(Commission File Number)

**98-1136802**  
(I.R.S. Employer Identification Number)

**251 Consumers Road, Suite 1105, Toronto, Ontario, Canada M2J 4R3**  
(Address of Principal Executive Offices) (Zip Code)

**647-479-9828**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	APTO	Nasdaq Capital Market

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 4, 2019, Aptose Biosciences Inc., or the "Corporation", held its Annual General Meeting of Shareholders. At the meeting, shareholders

voted in favor of all items of business, as indicated below:

**Proposal No. 1—Election of Directors**

The Corporation's shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2020 Annual General Meeting:

<u>Nominee</u>	<u>Votes For</u>	<u>% Votes For</u>	<u>Votes Withheld</u>	<u>% Votes Withheld</u>	<u>Broker Non-Votes</u>
Ms. Carol G. Ashe	8,948,469	99.39	54,620	0.61	19,413,447
Dr. Denis Burger	8,945,198	99.36	57,891	0.64	19,413,447
Ms. Caroline M. Loewy	8,949,720	99.41	53,369	0.59	19,413,447
Dr. Erich Platzer	8,942,016	99.32	61,073	0.68	19,413,447
Dr. William G. Rice	8,960,749	99.53	42,340	0.47	19,413,447
Dr. Mark D. Vincent	8,945,260	99.36	57,829	0.64	19,413,447
Mr. Warren Whitehead	8,938,937	99.29	64,152	0.71	19,413,447

**Proposal No. 2—Appointment of Independent Registered Public Accounting Firm**

The Corporation's shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders' meeting or until a successor is named.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
28,266,388	99.47	106,747	0.38	43,401	0

**Proposal No. 3—Amendment to By-Law No. 2**

The Corporation's shareholders voted to approve amendments to by-law No. 2 which increases the quorum for any meeting of shareholders to two persons present at the opening of the meeting who are entitled to vote thereat either as shareholders or as proxy holders and holding or representing not less than 33-1/3% of the outstanding common shares entitled to be voted at the meeting.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
8,831,049	98.09	114,223	1.27	57,817	19,413,447

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

[Exhibit 99.1. Press release. dated June 4, 2019](#)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Aptose Biosciences Inc.**

Date: June 4, 2019

By: /s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer